Related Experiment Videos
[Do drugs in pregnancy modify neonatal jaundice?]
1Institut für Pharmakologie und Toxikologie, Ernst-Moritz-Arndt-Universität Greifswald.
Zentralblatt Fur Gynakologie
|January 1, 1993
Summary
Maternal drug use during pregnancy may increase neonatal jaundice risk, particularly with drugs affecting uterine motility like oxytocin and ritodrine. While associations exist, clinical significance is limited unless other risk factors are present.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Perinatal Care
Context:
- Investigates the link between maternal drug administration and neonatal hyperbilirubinemia.
- Reviews literature on drugs suspected of causing elevated bilirubin levels in newborns.
- Highlights conflicting results regarding drug effects on neonatal jaundice.
Purpose:
- To collect and analyze data on drugs potentially causing neonatal jaundice.
- To explore the association between prenatal drug exposure and infant bilirubin levels.
- To describe potential mechanisms of drug-induced icterogenic effects.
Summary:
- Maternal drug use before or during delivery is associated with increased neonatal jaundice.
- Drugs affecting uterine motility, such as oxytocin and ritodrine, may have an icterogenic effect.
- Most studied drugs show contradictory results regarding their impact on neonatal hyperbilirubinemia.
Impact:
- Identifies specific drug classes (oxytocin, ritodrine) with potential neonatal jaundice risks.
- Emphasizes that clinical consequences are minimal unless additional risk factors for bilirubin encephalopathy are present.
- Provides a review of current literature for healthcare providers managing neonatal jaundice and maternal drug exposure.